BST Trade Alert
BST Trade Alert – January 22, 2016
Recommendation: Buy ImmunoGen (NASDAQ: $IMGN) up to $11.00 per share. About the Company: ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADC) that are designed to fight cancer. They developed the ADC technology to enable the creation of better therapies for people with cancer. The concept of an ADC is simple: […]
BST Trade Alert – December 18, 2015
Recommendation: Buy Insmed (NASDAQ: $INSM) up to $20.00 per share. About the Company: Insmed is a biopharmaceutical company focused on developing drugs to treat rare diseases. They are developing novel, targeted therapies to help service the unmet needs of these patients. About the Drug: Insmed currently has 1 drug, ARIKAYCE, in clinical testing. ARIKAYCE is […]
BST Trade Alert – November 20, 2015
Recommendation: Buy CoLucid Pharmaceuticals (NASDAQ: $CLCD) up to $5.00 per share. About the Company: CoLucid Pharmaceuticals is a clinical-stage pharmaceutical company. They are developing an innovative and proprietary small molecule for the treatment of migraine headaches. The company was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in […]
BST Trade Alert – October 8, 2015
Recommendation: Buy Anthera Pharma (NASDAQ: $ANTH) up to $7.00 per share. About the Company: Anthera Pharmecuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, IgA nephropathy, and exocrine insufficiency due to cystic fibrosis. The company focuses on treatments and medicines with current unmet needs. Anthera […]
BST Trade Alert – September 25, 2015
Recommendation: Buy OncoMed Pharmacueticals (NASDAQ: $OMED) up to $16.00 per share. About the Company: OncoMed is a clinical-stage company that researches and develops anti-cancer stem cell and immuno-oncology therapeutics. OMED has seven anti-product candidates in clinical development. OncoMed was founded with a focus on cancer stem cells which are a subpopulation of cells in a […]
BST Trade Alert – September 4, 2015
Recommendation: Buy NewLink Genetics (NASDAQ: $NLNK) up to $50.00 per share. About the Company: NewLink Genetics was established in 1999 and focuses on immunotherapy for cancer treatment. When the company first started, they were focused on either the ability of a tumor to suppress the immune system or the immune system itself, being unable to […]
BST Trade Alert – August 31, 2015
Recommendation: Buy Capricor Therapeutics (NASDAQ: $CAPR) up to $5.00 per share. About the Company: Capricor Therapeutics is focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. They are doing some interesting things in the field of cardiovascular disease. Their lead programs target post myocardial infarction (heart attack), heart failure […]
BST Trade Alert – July 24, 2015
Recommendation: Buy Macrocure NASDAQ: $MCUR up to $15.00 per share. About the Company: Macrocure is a clinical stage biopharmaceutical company. Their focus is the development of a way to treat chronic and hard-to-heal wounds. These are things like diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Their approach is to treat and close chronic […]
BST Trade Alert – June 9, 2015
Recommendation: Buy Celldex Therapeutics $NASDAQ: CLDX up to $28.00 per share. About the Company: Celldex believes the best way to treat and destroy many of the worst diseases is by harnessing the power of the immune system. They seek to leverage the power of the immune system’s response by combining therapeutic approaches to maximize the […]
BST Trade Alert – May 20, 2015
Recommendation: Buy Progenics Pharmaceuticals $NASD: PGNX up to $6.00 per share. About the Company: Progenics’ goal is to become a preeminent oncology company focused on developing innovative drugs to improve the lives of prostate cancer patients. Their pipeline includes therapeutic and diagnostic candidates in pre-clinical through late-stage development. They have one treatment, RELISTOR, that is approved […]
